Fennec's Pedmark To Reduce Risk Of Ototoxicity Associated With Cisplatin Scores FDA Nod

Fennec Pharmaceuticals Inc. (FENC, FRX) said on Wednesday that the FDA has approved Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.

Pedmark is the first and only FDA approved therapy for the above indication, an area of significant unmet medical need.

In Europe, the drug, under the brand name PEDMARQSI, is currently under evaluation by the European Medicines Agency.

FENC closed Tuesday's trading at $7.63, up 15.78%. In pre-market trading Wednesday, the stock is up 0.13% at $7.64.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT